Dear colleagues,

Welcome to the first edition of our MCO ECE newsletter. This will be a quarterly communication, and is designed to keep everyone informed with what is happening in our region.

It is a collaborative effort, with many teams and functions providing input. We hope that it will provide you with an overview of various activities from your colleagues, and help bring us all closer together. Within MCO we would like to share news and information with employees, recognize work well done, and update you on our achievements.

In this edition you will find lots of news - from our financials and year-ahead objectives, to training projects and cycle meetings. You will also see features on various departments and individual colleagues to help us all get to know one another while helping us to have a greater understanding of the structure of our MCO.

If you would like to share a story with us in the next edition, please contact Nuria Pascual at Nuria.Pascual@takeda.com

In the meantime, the newsletter needs a name! In the spirit of collaboration, we would like to open this up to colleagues to share suggestions. Please put your creative thinking caps on and feed any ideas back to Nuria Pascual by 30 September and win a prize.

We hope you find this communication useful, and we look forward to sharing more news with you in the future.

Sincerely,

Boris Braun

FinancialsMCO ECE financial results for the fiscal year 2013/14 are out now and our performance indicates that we achieved above our targets for the year.

read more

Inside MCO ECEIn each edition of this newsletter we will be introducing one or more of the MCO ECE functions providing you with an overview of their roles, responsibilities and objectives.

read more

News and EventsECE MCO ‘Leading Together’ in Bratislava Hold the date – cycle meeting in Croatia Heads of HR meet in Prague Office move in Croatia

read more

ProjectsLaunched in March, a new Quality Management System (QMS) specific to the MCO ECE has been introduced to ensure the region continues to forge ahead, whilst operating in a compliant manner.

read more

ADCETRIS SymposiumAn ADCETRIS symposium was hosted recently at Olomouc Haematology Days (OHD) - the largest congress of the Czech Society of Haematology.

read more

back to menu

In each edition of this newsletter we will be introducing one or more of the MCO ECE functions providing you with an overview of their roles, responsibilities and objectives.

In this first edition Medical Director, Vlasta Hejrova and BU Head Oncology/Hospital, Stanislav Šmerda, give us an insight into their departments.

Inside MCO ECE

Oncology and Hospitals Business Unit

The Oncology and Hospitals Business Unit (BU) provides Takeda’s customers with access to modern medicines that meet the growing needs of patients.

As the BU Head, I am supported by three Brand Managers, two Commercial Managers, 10 Key Account Managers (KAM) and one assistant.

We concentrate on targeting the survival rates of oncology patients suffering from Hodgkin’s lymphoma and osteosarcoma. We are also using our experience in chronic debilitating inflammatory diseases such as inflammatory bowel disease, to secure a brighter future for these patients.

Last year we made a significant contribution to MCO ECE sales – exceeding targets by 19% delivered through a new approach to KAM. And we have a lot to look forward to this year. We will be working hard with the launch of Entyvio, Tachosil Midi and Pre–rolled across the whole ECE region and Adcetris in Croatia.

Stanislav ŠmerdaBU Head Oncology/Hospitals

MCO ECE Medical Department

The Medical Department provides strategic expertise to all business activities in the MCO ECE, in line with the global strategy.

As Medical Director, I support the development and implementation of new processes across the five ECE countries, and provide medical support to cross-functional teams to support new launches or reimbursement applications.

There are 17 team members in the department with lots of varied roles. For example, Medical Affairs colleagues oversee documentation for regulators and control the quality of marketing documents, communications and publications. Meanwhile our Drug Safety Officers collect, process and evaluate information on serious adverse events and prepare safety reports for the authorities.

Our goal for the next year is to foster a culture of cross-functional collaboration. We hope to develop a talented, highly engaged team who can effectively support new product launches and implement the company strategy.

Vlasta HejrováMCO ECE Medical Director

The Medical Department ethos:

Coming together is a beginning; Keeping together is progress; Working together is success!

Henry Ford

Stanislav Šmerda’s message:

Be a strong, capable person, and devote the best of yourself for the success of the whole team.

MCO ECE newsletterSummer 2014

MEET: VACLAV FIURASEK AND RUŽENA KALEČÍKOVÁ read more

back to menu

Multi Country Organisation (MCO) ECE financial results for the fiscal year 2013/14 are out now and our performance indicates that we achieved above our targets for the year. Sales benefitted from the contribution of Controloc, Ebrantil, and the successful launch of Adcetris. These factors helped to offset the effects of price cuts which we had in Czech and Croatia. Overall, Takeda’s sales rose by 2% vs plan to 66.2 Million Euro. We delivered on our targets despite facing some major restructuring in November 2013, as well as price changes and a complex external environment. We faced a challenging situation to build the organization for tomorrow, and with that came some difficult decisions, however it has been encouraging to see that the ‘MCO as One Country Concept’ is starting to resonate with the global teams as well as the Zurich support functions teams.

Another positive development was the recent approval of alogliptin and alogliptin-metformin for reimbursement in Hungary; a tremendous step forward in strengthening Takeda’s position in treating type 2 diabetes within the MCO ECE territory. We believe we will have the product on positive lists in the whole of MCO ECE by year end. Together with pantoprazol we have a fantastic growth opportunity for the future success of the organization.

The fiscal year 2014/15 has started very positively, but we are aware the challenges that we will face with price changes and competition pressure, especially with generics in some territories. Our key objective is to perfectly plan and execute the important product launches ahead of us.

With product launches keeping momentum in oncology and respiratory, we are in a very favorable position. We are keeping alive our ‘one country’ spirit, staying patient focused and putting structures and processes in place in order to deliver on our promises to patients across MCO ECE now and for the future.

Thank you all for your terrific work and keep up the good work in the future.

Boris Braun

Financials

THE INTERNAL NEWSLETTER FOR EASTERN & CENTRAL EUROPE

R&D (previously

CMSO)

PDD, QA

Reporting

Escalation

A new Quality Management System (QMS) specific to the MCO ECE, was launched in March to ensure the region continues to forge ahead, whilst operating in a compliant manner.

The MCO ECE structure has resulted in employees now having responsibilities in more than one country or even in all five, and the QMS helps to support them to be aware and follow each country’s internal rules and external legislation and codes.

The QMS introduces short and long-term quality standards to the MCO ECE bringing together Finance, HR, Compliance, Medical and Regulatory SOPs.

Natasa Vresk Medical Advisor and Regulatory Manager commented: “We work in a very matrix orientated environment, and daily work can sometimes be very challenging. Joint organization not just increases our visibility outside the MCO ECE borders, but also provides many advantages for the people working here.

“It allows us to bring together bigger, more experienced teams and learn from each other by sharing best practices.”

New MCO ECE Quality Management System

Projects

External training boosts skills for sales force in Croatia

The pharmaceutical market is constantly evolving, and to ensure the sales force are prepared for the challenges they face in the field, the team in Croatia have recently undergone a new training programme.

Developed by external training company RMI inc, the programme took place over two days in March in Slovenia, ahead of the first MCO Cycle Meeting.

The programme was designed to support the sales team in recognising Takeda’s valuable customers, looking at the behaviour, economic value and adoption ladder to help identify any unmet needs. The purpose was to equip the sales force with an understanding of how to develop tailored communications that can fit each individual customer’s style.

Before the course began, each attendee worked with a trainer to identify where they could further develop their skills and were set objectives. Then through various workshops, role plays and real life examples, they worked on adopting a communications style to suit different profiles of customers.

Aleksandra Ogorevc, Commercial Head for Croatia and Slovenia, said: “There was some scepticism in the air before the training, but I am delighted that the feedback has been so positive. We face many challenges in the market; to remain competitive we have to make sure our operating model meets our customers’ needs. We hope that this training will give our sales force the knowledge and support they need in order to win in the field.”

The sales force will be involved in ongoing training sessions in the future to ensure continual development for the team.

This training was also implemented for Sales Force in Hungary and will be offered to Czech Republic very soon.

What colour personality are you?!

The MCO ECE Management Team have recently undergone a training exercise to discover their personal thinking styles and learning preferences, defined by “brain dominance theory”. The methodology of the training was based on the popular Ned Herrmann theory, which categorizes individuals into colours.

During the workshop, the team took part in various tasks to understand their personality type, in order to identify their preferred way of thinking and communicating.

Brain dominance theory has been used for decades as a way to improve communication techniques, and the Management Team will be looking at ways to bring the training to the whole organization.

What colours do you think make up the Management Team? Email your answers to Nuria Pascual at Nuria.Pascual@takeda.com by 30 September and win a prize.

BLUEAuthoritativeDirectiveAll-businessAnalyticalFactual

BLUEFacts, no fluffTechnical accuracyArticulated ideasCritical analysisStraightforward

Managementstyles

Communication preferences

YELLOWAdventurous

VisionaryEntrepreneurial

IdealisticHolistic

YELLOWMetaphorsBig PictureImaginativeConceptual

Visual

GREENTraditionalConservativeOrganizedAccountableSafe-keeping

GREENDetailsAction plans ExplanationsStay on-topicThoroughness

RED Team-oriented

SupportivePersonable

IntuitiveCommunicator

RED Expression

Open discussionPersonal touch

EmpathyStories and discussion

ECE MCOCCO

Compliance Procedures

∞ Local System Description ∞ Local QMS ∞ GDP ∞ GMP ∞ Business activities in QMS (HR, Finance etc.)

∞ PV & PMP in CTM ∞ GCP ∞ Medical Affairs ∞ Regulatory Affairs ∞ All other activities rel. to R&D

CQA

Monthly reporting and reporting of issues (traffic light)

Reporting

Escalation

PDD QMS

back to menu

News and Events

ECE MCO ‘Leading Together’ in Bratislava

The first cycle meeting for MCO ECE was held on March 10-13, 2014 in Bratislava, Slovakia. The meeting was opened by Boris Braun, Head of MCO ECE. Boris remarked that the MCO ECE has gone through a lot of changes, very successfully and said, “People are normally nervous of changes, but if you don’t change you never know what you miss.”

The meeting provided an update on the unification of processes within MCO ECE, since the amalgamation of the internal processes (policies, SOPs, finance, legal, etc.), and focused on the planned campaign period for the next six months.

Attendees were briefed on the product pipeline for the region, with product overviews presented by the Brand Managers of the different therapeutic areas.

Lukáš Kalus, Business Unit Manager Retail CZ & SK commented, “I would like to wish everyone the best of luck for the upcoming period. Trust in our teams and mutual cooperation across borders will be the key to our success across ECE MCO, which is already delivering great results. Let‘s follow our motto: ‘Leading Together’”.

The meeting was attended by 115 employees from across the MCO ECE region and welcomed several guests from Takeda. Attendees also heard from members of the Management Team, including presentations from: Lucie Stabrynová, Compliance Officer; Vlasta Hejrová, Medical Director; Nuria Pascual, Head of Human Resources; and Elmar Zagler, Head of Finance. The team would like to thank colleagues for their cooperation in the organization of this meeting namely, Stanislav Šmerda, Jana Ondráčková and Jitka Caberová.

Hold the date – cycle meeting in Croatia

Following the successful meeting in Bratislava, the next cycle meeting will take place in Rovinj, Croatia, week commencing September 22, 2014.

This will be an opportunity to look back at the previous six months, but importantly is a chance to focus on two products being launched in Hungary and other ECE MCO countries, this autumn.

• Controloc Magna (also braneded as Tecta and Pantonovo) is a proton pump inhibitor (PPI) used for the treatment of reflux esophagitis, gastric and duodenal ulcers, Zollinger-Ellison-Syndrome and other pathological hypersecretory conditions

• Vipidia and Vipdomet is an original product from Takeda and indicated for controlling blood sugar level of Type 2 Diabetes patients

More details to follow.

Heads of HR meet in Prague

The MCO ECE hosted the meeting of the heads of HR, with representatives from across different countries within the EUCAN region (and some further afield) in Prague on May 14-16, 2014.

The meeting, attended by participants from the UK, Nordics, Iberia, Germany, Canada, Italy, France, Poland, Switzerland, Austria, Balkans, ECE, Tokyo and Dubai, provided a platform to discuss Takeda’s global HR strategy, update on ongoing projects and exchange best practice examples.

Delegates heard a presentation from Dave Osborne, Global HR Officer, who provided an update on Takeda’s global HR strategy, and Antonio Pregueiro, Head of Business Operations & Implementation on the Key Account Management (KAM) training and In-field Capabilities roll out. Boris Braun, Head of ECE introduced this MCO to the audience.

Efi Stavropoulou, HR Head MCO Balkans, said “It was a pleasure meeting with my colleagues and I am looking forward to the initiation and implementation of the many interesting and fundamental HR work streams.”

Office move in Croatia

The Croatian local team have moved to new offices in Zagreb. In keeping with Takeda’s global image, the new space is a professional, modern and bright environment.

A special thanks goes to all those in involved in the move, including Aleksandra Ogorevc, Danijela Benkus, Natalija Oreski, Ivana Barbic Kovacic and Jelena Vidmar Kruzic for their hard work and support.

back to menu

ADCETRIS Symposium

An ADCETRIS symposium was hosted recently at Olomouc Haematology Days (OHD) - the largest congress of the Czech Society of Haematology. The main objective of the symposium was to raise awareness of Hodgkin’s lymphoma and the unmet medical need in this area.

Despite stiff competition, over 70 attendees participated in the symposium, where three key speakers gave outstanding presentations. Professor Plank, pathologist (Slovakia), Dr Prochazka, a haematologist (Czech Republic) and Professor Engert Hodgkin lymphoma expert (Germany) all helped to bolster the quality of the meeting.

The symposium helped to bring Takeda and ADCETRIS into the spotlight of the Czech haematology community and helped raise awareness of its value for patients and health care professionals.

back to menu

Meet

Vaclav FiurasekCommercial Excellence Head

In my role as Commercial Excellence Head, my focus is on developing business strategies across all five countries in the ECE MCO. I am responsible for reviewing and improving our business and planning processes so we can achieve commercial excellence, and ensure we have good communication between the individual countries and the BO&I team in Zurich.

On a daily basis I work with our Finance Managers to ensure effective regional management, looking at country profitability, ROI and short and medium-term planning. I also work closely with the sales team to deploy our sales force effectiveness strategy – this means looking at their geographical deployment, capabilities, allocation of resources, as well as assessing training needs.

It’s a demanding role – every day I must work with many functions of the business to ensure our approach is delivering the best it can for the business. Working across five countries, all with different languages, regulatory, pricing and reimbursement systems can be challenging, particularly when preparing for the launch of new products. But it is this that excites me the most; I have worked on 15 product launches since I started work in the pharmaceutical industry!

When I’m not working, I find the best way to relax is playing ice hockey. It’s hard and fast, but a great team game which I love to play.

Meet

Ružena Kalečíková Market Access Manager for Slovakia

In its simplest form, Market Access is how we get our drugs to market and make them available for patients, so it is an essential part of our business and plays a critical role in our success. My role is to manage the development and implementation of our pricing and reimbursement strategies for new and existing portfolios, and ensure these meet all legislative requirements.

I am a real team-player, which is critical in my role. Internally I work closely with the Medical, Sales and Marketing departments to ensure our market access strategies are successful. I also build and maintain robust relationships with external stakeholders – local authorities, health economic opinion leaders, patient groups and reimbursement agencies.

It is a challenging job, with lots of hurdles, and no ‘one-size-fits-all’ solution. For each product or therapy area we have to customize our approach, but I relish the opportunity, particularly when we are introducing new drugs. I have been in the pharmaceutical industry for 23 years and in Market Access for the last 10, and it is the innovative portfolio of Takeda that excites me the most. I get real job satisfaction from this.

In my spare time I love spending time with my family and friends. I also enjoy playing golf, travelling and painting.

back to menu